| dc.description.abstract | The most widespread and severe forms of idiopathic inflammatory bowel disease
(IBD) are Crohn's disease (CD) and ulcerative colitis (UC). There are now no approved
medical treatments for these disorders, and their pathophysiology is not fully understood.
Through a number of inflammatory mechanisms, chronic inflammation, and excessive
reactive oxygen species (ROS) generation have been linked together. There are numerous
pharmaceutical treatments for reducing intestinal inflammation, including the use of antiinflammatory drugs such as mesalamine. The majority of anti-inflammatory drugs are poorly
absorbed and have a low bioavailability, which decreases their therapeutic effectiveness and
amplifies their adverse effects when taken for a long time. Numerous pharmaceutical
delivery systems have been invented with the use of nanotechnology, however, the majority
of them have expensive production costs and are challenging to mass produce. This study's
aim was to explore silica-containing redox particles (siRNPs) made from an amphiphilic
block copolymer that has a drug-absorbent silica moiety and a ROS-scavenging nitroxide
radical moiety in the hydrophobic segment. To improve the stability and regulate the drug's
release into the digestive system, this method was researched. Using the dialysis approach,
mesalamine-loaded siRNP (MES@siRNP) with a diameter of around 120 nm was used as a
nanocarrier for mesalamine. By using the 2,2'-azinobis(3-ethylebenzothiaziline-6-sulfonate)
(ABTS) and 2,2'-diphenyl-1-picrylhydrazyl (DPPH) assays, MES@siRNP samples
displayed antioxidant activity. A lipopolysaccharide-induced macrophage cell line activation
and albumin denaturation paradigm were used to assess the anti-inflammatory activity in
vitro. A new anti-inflammation nano-formulation with this combination showed promise and
merits of future study. | en_US |
